Redirected T‐cell cytotoxicity to epithelial cell adhesion molecule‐overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model

To redirect cytotoxic T cells to target a broad range of adenocarcinomas, the authors constructed a novel, recombinant, bispecific antibody, E3Bi, directed at the tumor‐associated antigen, epithelial cell adhesion molecule (EpCAM), and the CD3 receptor on T cells.

[1]  Hui Peng,et al.  Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. , 2002, Cancer letters.

[2]  K. Tsumoto,et al.  A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma , 2002, Cancer Immunology, Immunotherapy.

[3]  R E Fulton,et al.  Bispecific and bifunctional single chain recombinant antibodies. , 2001, Biomolecular engineering.

[4]  N. James,et al.  A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer , 2001, British Journal of Cancer.

[5]  T. Valerius,et al.  Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. , 2001, Critical reviews in oncology/hematology.

[6]  H R Hoogenboom,et al.  Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.

[7]  L. Weiner,et al.  Introduction: bispecific antibodies. , 2001, Journal of immunological methods.

[8]  S. Withoff,et al.  Bi-specific antibody therapy for the treatment of cancer. , 2001, Current opinion in molecular therapeutics.

[9]  M. Little,et al.  Recombinant chimeric OKT3 scFv IgM antibodies mediate immune suppression while reducing T cell activation in vitro , 2001, European journal of immunology.

[10]  M. Little,et al.  Of mice and men: hybridoma and recombinant antibodies. , 2000, Immunology today.

[11]  M. Little,et al.  Treatment of Human B Cell Lymphoma Xenografts with a CD3 × CD19 Diabody and T Cells1 , 2000, The Journal of Immunology.

[12]  H. Nelson,et al.  Current perspectives of bispecific antibody-based immunotherapy. , 2000, Journal of biological regulators and homeostatic agents.

[13]  Weiner Lm.  Bispecific antibodies in cancer therapy. , 2000 .

[14]  U. Wetterauer,et al.  Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. , 2000, Anticancer research.

[15]  G. Riethmüller,et al.  The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. , 2000, Cancer research.

[16]  B. Bodey,et al.  Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. , 2000, Current pharmaceutical design.

[17]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[18]  L. Weiner,et al.  Bispecific antibodies in cancer therapy. , 1999, Current opinion in immunology.

[19]  S. Batra,et al.  Single‐Chain Antibodies in Pancreatic Cancer , 1999, Annals of the New York Academy of Sciences.

[20]  T. Ley,et al.  How do cytotoxic lymphocytes kill their targets? , 1998, Current opinion in immunology.

[21]  M. Moser,et al.  In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model. , 1998, Journal of immunology.

[22]  M. Mack,et al.  Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer , 1997, Cancer Immunology, Immunotherapy.

[23]  G. Tzanakakis,et al.  In vivo selection of a highly metastatic cell line from a human pancreatic carcinoma in the nude mouse , 1992, Cancer.

[24]  R K Jain,et al.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. , 1990, Cancer research.

[25]  R K Jain,et al.  Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. , 1988, Cancer research.

[26]  M. Herlyn,et al.  CO 17-1A and related monoclonal antibodies: their production and characterization. , 1986, Hybridoma.

[27]  G. Hayman,et al.  Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. , 2000, Human gene therapy.

[28]  P. Hwu,et al.  Recognition of human colon cancer by T cells transduced with a chimeric receptor gene , 2000, Cancer Gene Therapy.

[29]  Yanjun Liu,et al.  Bi-specific antibodies in cancer therapy. , 2002 .

[30]  J. V. D. van de Winkel,et al.  Immunotherapeutic perspective for bispecific antibodies. , 2000, Immunology today.